Rabab Khodary is a distinguished Senior Expert in Market Access, Pricing, and Health Economics, widely recognized for her strategic mastery at the intersection of medical innovation and the evolving Saudi Arabian healthcare ecosystem. Bridging a robust scientific foundation with executive leadership, she holds a BSc in Medical Technology from King Abdulaziz University and an MSc in Cell and Molecular Biology from San Francisco State University, bringing unique analytical rigor to commercial and health policy frameworks.

With over a decade of high-impact experience spanning world-leading pharmaceutical multinationals including GSK, Johnson & Johnson , Vertex Pharmaceuticals, and Novartis, Rabab has successfully commercialized and managed thirteen complex therapy areas. Her expertise ranges from high-stakes Hemato-Oncology to cutting-edge Cellular and Gene Therapies.

A pioneering thought leader reshaping the region's pharmaceutical landscape, Rabab currently serves as an Advisory Board Member for the Health Technology Assessment (HTA) Office. She is a prominent voice in shifting the industry from transactional commercial models to transformational, value-based healthcare systems aligned with Saudi Vision 2030. Frequently featured in major media like Arab News and top-tier industry podcasts, Rabab is a strong champion for local capability building, executive mentorship, and the integration of high emotional intelligence (EQ) and mental well-being into senior leadership